Slide 1: Research & Development
Exhibit 99.1 Research & Development March 3, 2006 Jerry Cagle Scott Krueger Robert Stevens
Slide 2: R&D Areas of Experience
R&D Areas of Experience SURGICAL THERAPIES CONSUMER PHARMACEUTICAL AND THERAPIES PRODUCTS DEVICES
Slide 3: Alcon R&D Focus
Alcon R&D Focus Refractive Glaucoma IOL Infection BSS Plus Retinal Viscoelastics Therapies Knives, Otic Needles & Infection Sutures Therapies Surgical Nasal Instrumentation Therapies & Disposables Allergy Custom Paks Contact Lens Dry-Eye Punctal Ocular OTC Inflammation Care Plug Vitamins Therapies
Slide 4: R & D Organization
R & D Organization 1,235 857 95 43 143 9 88 Ft. Worth R&D Japan Irvine Grieshaber Orlando -Huntington Int’l Dev -Sinking Springs M.D./O.D./Ph.D M.S. B.S. Tech./ Support 296 233 407 299
Slide 5: Worldwide Ophthalmic R&D Sites
Worldwide Ophthalmic R&D Sites Orlando Fort Worth Barcelona Irvine ~1,200 Employees Facilities in Texas, California, Florida, Spain ~ 250 Product Registrations/year Next 5 years = $2.5 Billion in R&D
Slide 6: Commitment to R&D 1999-2005
Commitment to R&D 1999-2005 500 450 422 390 $ Millions Per Year 400 350 350 323 290 300 246 250 213 200 150 100 50 0 1999 2000 2001 2002 2003 2004 2005
Slide 7: Scott Krueger
— o) a co) =) — < aa fe) 3) op)
Slide 8: Agenda
Agenda • Glaucoma • Dry Eye • Retaane • Patanase • Anti-infective/Anti-Inflammatory
Slide 9: Product Pipeline
Product Pipeline Glaucoma Travatan Dosing Aid (US/EU) DuoTrav (EU) Travatan BAC Free (US) Travatan (Japan) Dry Eye 15(S) Hete TBD Rimexolone 2006 2007 2008+
Slide 10: Dry Eye Disorder
Dry Eye Disorder Result in an abnormal tear film & tear function Dry eye is the result of any number of unrelated causes or conditions.
Slide 11: Rimexolone: Change in Total Corneal Staining
Rimexolone Change in Total Corneal Staining 0 14 28 42 0 -0.2 Rimexolone 0.2% Change in Total Corneal Staining -0.4 Rimexolone 0.075% -0.6 Vehicle -0.8 -1 -1.2 -1.4 -1.6 -1.8 Day
Slide 12: Rimexolone: Composite Dry Eye Symptoms
Rimexolone Composite Dry Eye Symptoms 12 Composite Dry Eye Symptoms 10 8 6 4 Rimexolone 0.2% 2 Rimexolone 0.075% Vehicle 0 0 7 14 21 28 35 42 Day
Slide 13: Retaane Update
Retaane Update • Retaane approved in Australia 12/05 • US and EU request additional data from ongoing or new studies • Studies in progress and planned – IDEAA dose regimen study – NEI study with monclonal antibody VEGF inhibitor – EU placebo controlled study • AART - Risk Reduction Study – Fully enr
Slide 14: Patanase Update
Patanase Update • FDA requested reformulation of Patanase – Formulation issue unrelated to Patanol • Met with FDA to discuss pathway forward – Very satisfied with efficacy – Ensure safety in expected broad use • Next Steps – Reduce Inactive Ingredient – Clinical Studies – Amend NDA 2007
Slide 15: Product Pipeline
Product Pipeline Anti-Infective/Anti-Inflammatory Vigamox (Japan) Moxifloxacin AF (US) Moxidex Otic (US) Moxidex Ophthalmic (US) 2006 2007 2008+
Slide 16: Jerry Cagle
Jerry Cagle
Slide 17: Alcon is Positioned for Long Term Success
Alcon is Positioned for Long Term Success • Diseases of the aging eye Glaucoma • 1-4% of population over 40 represent one of the last great • 67M patients worldwide, 5-6M in US areas of unmet medical need • 7M are bilaterally blind from glaucoma • Favorable demographics • Significant resources for d
Slide 18: A Strategic Advantage
A Strategic Advantage Mine all sources of pipeline compounds De novo Re-positioning proteins In-licensing Re-formulating REWARD Small markets Nature Reviews Drug Discovery 3;673:2004 RISK
Slide 19: Focused collaborations are increasingly important
Focused collaborations are increasingly important • Allow us to partner with companies whose expertise complement ours • Technology changes rapidly. Collaborations allow us to get what we need, when we need it, with little amortization. • “Renting” versus “Buying” allows for greater flexibility in u
Slide 20: Small Molecule Drugs vs. siRNA
Small Molecule Drugs vs. siRNA Small Molecule Drugs siRNA DNA DNA mRNA mRNA siRNA Protein Drug Protein • Binds to active site on protein • Direct cleavage of mRNA • Inhibit protein function directly • Inhibit production of protein • 1 molecule of drug binds 1 receptor • 1 siRNA can inhibit 1000 rece
Slide 21: Albany Molecular
Albany Molecular We are searching for molecules that affect water movement into and out of cells. Albany has expertise in natural products with the world’s largest collection of natural product lead-finding libraries A team of natural product experts with decades of experience in the field and worki
Slide 22: Origenis: Novel Chemistry Technology
Origenis: Novel Chemistry Technology • Conventional • Origenis – Structure Based Design – Electronic and Steric Field Based – Structures chosen based on Design what looks similar to parent – Structures chosen based on – Multiple Step Synthesis proprietary algorithm to select functionally similar “ch
Slide 23: Jerini- ANP/CNP
Jerini- ANP/CNP Jerini’s P2D Process 1. Minimization of peptide 2. Generation of non-peptide drug 3. Proven successes Bradykinin receptor antagonists Complement C5R (BOTH are in clinical studies)
Slide 24: Kalypsys: A powerful de novo discovery engine
Kalypsys: A powerful de novo discovery engine De Novo discovery requires increasingly expensive and rapidly changing technology, proprietary libraries for screening, and generous medicinal chemistry resources
Slide 25: Kalypsys: A powerful de novo discovery engine
Kalypsys: A powerful de novo discovery engine
Slide 26: Summary
Summary • The Alcon Ophthalmology Discovery Pipeline is robust and strong • We are not content. We continue to seek new pharmacophore opportunities worldwide regardless of the source
Slide 27: Robert Stevens
7) c ) > o) aS op) ~ — o) we) fe) a
Slide 28: Surgical Products R&D: AcrySof Franchise
Surgical Products R&D Acrysof Franchise • AcrySof® ReSTOR IOL – AcrySof ReSTOR Natural IQ – AcrySof ReSTOR Natural IQ Toric • AcrySof® Toric • Phakic Refractive IOL • AcrySert® Delivery System
Slide 29: ReSTOR Apodized Diffractive IOL
ReSTOR Apodized Diffractive IOL • Novel, patented optical design • Optic with apodized diffractive central zone - unique optical design matches performance to vision needs 100 92 Physician 90 80 80 74 experience % of Subjects 70 59 69 ReSTOR (N=339) greater than 60 50 41 Array (N=99) ReZoom (N=215)
Slide 30: AcrySof Toric: Corneal Astigmatism
Acrysof Toric Corneal Astigmatism Corneal curvature is different in two meridians causing a defocused image No Astigmatism 1.50 D cylinder @ 90 degrees
Slide 31: Cylinder Distribution
Cylinder Distribution 50.0 N = 10,411 40.0 30.0 Moderate % of Patients 1.0 – 2.0D 25% 20.0 Severe >2.0 D 10.0 10% 0.0 <.5 <1 <1.5 <2 <2.5 <3 <3.5 >3.5 Cylinder D ( < )
Slide 32: AcrySert Delivery System Update
AcrySert® Delivery System Update
Slide 33: Product Specifications
Product Specifications 6.0 mm Model Model OAL L12500 12.5 mm L13000/ 13.0 mm RA6M13 L13500/ 13.5 mm RA6M35 L14000/ 14.0 mm RA6M14 Dioptric Range: -6.0 D to -16.5 D
Slide 34: NGVS: Next Generation Vit System
NGVS: Next Generation Vit System •Power IV Pole •Footswitch •Monolith look •Venturi Fluidics •U/S Performance •Pneumatics Drivers •Quick + Pack •Diathermy •Vit Cutters •Phaco handpieces •VFC Functionality •AquaLase •Pak Strategy •User Interface elements •Footswitch •Remote Control •Peristaltic Desig
Slide 35: LADAR6000 Development Strategy
LADAR6000 Development Strategy: Improve ease of use and overall reliability . Key Feature Enhancements Improved Illumination New Laser Engine Improve Internal Software Linkages High Speed Ablation Assisted Registration Undilated Eye Tracking
Slide 36: Product Pipeline
Product Pipeline IOLs AcrySof Natural (Approved US/EU) Japan AcrySof ReSTOR (Approved US/EU) Japan AcrySof Toric (Approved US/EU) Japan AcrySof ReSTOR Natural IQ US/EU Japan TBD AcrySof ReSTOR Natural IQ Toric US/EU Japan TBD Instrumentation Next Generation Laser (Vit/Ret) US/EU Next Generation Vit/
Slide 37: Introducing Systane Free
Introducing Systane Free • No traditional Preservative • But, Preserved in the Bottle • And Preservative Free in the Eye • Suitable for use day and night— Less blur than traditional Gels • Comfort based on proven technology of recognized demulcents and HP-guar
Slide 38: OPTI-FREE RepleniSH
OPTI-FREE® RepleniSH™ • Compatible Disinfection – POLYQUAD® & ALDOX® • Cleaning – Citrate • Reconditioning – TEARGLYDE™
Slide 39: Slide 39